Drug Profile


Alternative Names: MIM-D3

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mimetogen Pharmaceuticals
  • Class Amides; Aza compounds; Cyclic ethers; Eye disorder therapies; Neuroprotectants; Nitrobenzoates; Small molecules
  • Mechanism of Action TrkA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dry eyes
  • No development reported Glaucoma

Most Recent Events

  • 01 Mar 2017 Mimetogen Pharmaceuticals completes two phase III clinical trials in Dry eyes in USA (NCT02665234; NCT02634853)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Glaucoma in Canada (Ophthalmic, Liquid)
  • 04 Nov 2015 Allergan and Mimetogen Pharmaceuticals enter into an exclusive licensing agreement for development and commercialisation of tavilermide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top